Skip to content
‹ Back to IndustriesHealthcare

Zoom's stake in Medaica aims to bring the physical exam into video visits

Zoom Ventures made an undisclosed strategic investment in Medaica, whose FDA-cleared M1 telehealth stethoscope supports real-time remote heart and lung auscultation. Zoom already integrates with EHRs including Epic, Oracle Cerner Millennium and Athenahealth, but an investment is not an integration and no combined product has been announced. Cardiology follow-ups and care facilities are highlighted as likely early use cases.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By MarketScale Newsroom · Zoom VenturesMedaicaMedaica M1Remote Auscultation
Share

Key takeaways

01

Video gave telehealth the patient's face; an FDA-cleared remote stethoscope adds the heartbeat, and Zoom now has a financial stake in that second layer.

02

Today's cleared capability is real-time heart and lung auscultation; the wider mix of third-party devices, AI analysis and decision support is still in development.

03

For health systems with elderly or rural cardiology panels, the sharper vendor question is how exam findings reach the EHR record of the visit.

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The video visit has always had a blind spot about the size of a stethoscope. On November 12, Medaica, a Henderson, Nevada medical intelligence company, announced an investment led by Zoom Communications. Zoom Ventures, Zoom's investment arm, made the strategic investment to speed development of what Medaica calls its Telehealth 2.0 platform. Medical Device Network noted that the value of the deal was not disclosed.

The money matters less than the hardware it backs. Medaica's current product, the M1 telehealth stethoscope platform, received FDA clearance in February 2025, according to Medical Device Network, and lets a clinician hear a patient's heart and lungs in real time from another location. Zoom, meanwhile, already sits inside the electronic health record systems many US health systems run every day.

Video gave telehealth the patient's face. Medaica's FDA-cleared stethoscope gives it the patient's heartbeat, and Zoom has now put money behind that second part. For a virtual-care director or health system CIO, that suggests the remote physical exam could become a device and workflow decision attached to platforms they already run, a different kind of purchase than another video license.

One cleared exam, a longer device roadmap

Stephen Randall, Medaica's CEO and co-founder, put the problem plainly in the company's announcement on Business Wire: "Telehealth transformed access to healthcare, but the physical exam remained in the clinic." His stated goal is a platform where clinicians can examine, detect, diagnose and monitor patients remotely in real time, built out into a set of medical devices, AI and diagnostic tools for homes and care facilities.

Pulse 2.0, in its coverage of the deal, spells out what that gap costs. Because physicians cannot perform many physical exams over video, patients may have to book additional in-person appointments for measurements, diagnostic assessments or monitoring. One encounter becomes two, and the second is the trip telehealth was supposed to spare the patient.

Clinical research had already pointed to the same gap. Julia Shaver, MD, of Kaiser Permanente Northern California, wrote a 2022 review in Primary Care that found care delivered by telemedicine can match in-person care for some acute and chronic conditions. The review also said more study is needed on how the telemedicine physical exam contributes to patient assessment. Medaica's cleared device focuses on one specific part of that exam: what a clinician hears through the chest.

What has been cleared so far is narrower than Randall's ambition, and the details matter. At the core of Medaica's platform is live heart and lung auscultation, which carries FDA clearance. The platform can also connect to clinical decision-support tools, AI-assisted analysis and third-party applications. Auscultation is the long-standing bedside practice of listening to sounds inside the body. Medaica's product lets a clinician do it remotely and live, while the visit is happening.

The same coverage describes the platform as designed to support examination, measurement, monitoring and assessment, with AI meant to help clinicians interpret what remote exams collect while clinical decisions stay with qualified professionals. That split matters for governance. A remote stethoscope that streams sound to a physician is a familiar kind of tool; an AI layer that flags findings is a different one, and the Zoom investment is meant to fund the build toward the second.

What is cleared versus what is planned: Medaica's FDA clearance covers its M1 platform for real-time remote heart and lung auscultation. Connecting additional third-party devices, AI-assisted analysis and decision-support tools is the development work the Zoom Ventures investment is meant to accelerate.

Zoom already has a seat in the EHR

This is far from Zoom's first healthcare move. Medical Device Network reports that since the pandemic the company has built integrations with Epic, Oracle Cerner Millennium and Athenahealth, and offers Zoom Clinical Notes, an AI dictation service for clinicians. Abhisht Arora, Zoom's chief strategy officer, framed the Medaica stake as an extension of that work: connecting clinicians, patients and staff wherever they are, and cutting administrative load.

Arora went further, saying Medaica is "establishing digital-first clinical examinations as a new standard for accessible, high-value, and on-demand healthcare delivery." That is ambition rather than evidence. Still, it suggests Zoom sees the exam as part of a standard virtual visit, not a niche add-on for a few specialties.

Read together, the pieces point one way. Zoom covers the conversation and, through Clinical Notes, the documentation. Medaica covers a slice of the exam, with a platform Pulse 2.0 describes as built to complement existing telehealth experiences rather than rely on video alone. An investment is not an integration, and neither company has announced a combined product. Still, a strategic stake from the company that runs the video layer indicates where Zoom thinks the next gap in a virtual visit lies.

The deal in four markers

Feb 2025
FDA clearance for Medaica's M1 telehealth stethoscope platform, the base the new money builds on
3 EHR vendors
Epic, Oracle Cerner Millennium and Athenahealth, where Zoom already has integrations
More than 1 hour
Distance from clinic for some of an Emory cardiologist's patients monitored remotely
5.95%
GlobalData's projected annual growth rate for the telehealth market through 2035

Medical Device Network; Business Wire (Medaica announcement); GlobalData via Medical Device Network

For health systems already running Zoom inside their EHR, this changes the question to ask in the next renewal. The issue shifts from whether video works to whether exam data, a recorded murmur or a lung sound, can travel into the same visit record as the conversation and the note.

Patients in their 90s, an hour from clinic

The strongest sign of real-world use comes from Dr. Byron Williams Jr., chief of cardiology at Emory Saint Joseph's and emeritus chief of medicine at Emory University Hospital Midtown. He said in the announcement that Medaica allowed him to track patients' murmurs and bruits remotely and in real time. Some of those patients are in their 90s, and their homes are more than an hour away from the clinic. Pulse 2.0 explains that bruits are abnormal vascular sounds that clinicians listen for when they assess blood flow.

That was liberating not only for us, but for my patients, some of whom are in their 90s and live more than an hour from the clinic. This technology can significantly expand the care that can be delivered remotely., Dr. Byron Williams Jr., Chief of Cardiology, Emory Saint Joseph's

That example shows where a remote stethoscope earns its keep first: cardiology and pulmonary follow-ups, where the exam is mostly listening and the patient finds the trip harder than the visit itself. Medaica also names care facilities as a target, and Pulse 2.0 points to residents who could get specialist evaluations without being transported to outside offices. For systems with large rural, elderly or homebound panels, those are the cohorts where a pilot would show results fastest.

Pulse 2.0 adds that remote exams could let clinicians monitor certain conditions more frequently while cutting unnecessary travel. For a murmur that a cardiologist is tracking over time, that frequency is the practical change: checks no longer have to wait for the patient to make the trip.

Remote care also has a familiar starting point in cardiology. The Primary Care review cites data showing that, as of 2018, 76% of US hospital systems were using telemedicine in some form, and the heaviest users were radiology, psychiatry and cardiology. It also cites a systematic review of 44 studies, which found that cutting out travel time was one of the factors most often tied to patient satisfaction with telehealth. Williams's patients are where those two findings meet: their specialty is already comfortable with remote care, and the drive to the clinic is long.

The counterweight is scale. GlobalData analysis cited by Medical Device Network projects the telehealth market, as GlobalData defines it, growing from $403m in 2025 to about $716m in 2035, at 5.95% a year. That is steady growth, not a land rush. The case for remote exams rests on specific patients who are hard to reach in person, which argues for targeted deployments over system-wide rollouts.

Questions for the next telehealth contract

Telehealth's own history offers a useful checklist. According to the Primary Care review, family medicine providers (N = 1,630) who did not use telehealth before the pandemic were more likely than users to name inadequate reimbursement, liability concerns, equipment costs and lack of training as obstacles. In early March 2020, Congress relaxed Medicare's rules on where telehealth could originate and what it would pay for. Before that change, telehealth had been limited to prespecified sites such as designated rural areas and certain medical facilities. Under the CARES Act and a CMS 1135 waiver, it could originate from any site, including the patient's home.

That history matters for a device like Medaica's. A remote stethoscope adds hardware to a visit that once needed only a screen, which could bring the old objections about equipment and training back into procurement talks. Nothing here forces a purchase this quarter. It does give virtual-care and procurement leaders a few sharper questions to put to Medaica, Zoom or any competing remote-exam vendor:

  1. Which exam capabilities are FDA-cleared today, and which are on the roadmap? For Medaica, the cleared answer is real-time heart and lung auscultation.
  2. How does exam audio or a finding reach the EHR record for that visit, and through which integration?
  3. Where AI-assisted analysis is offered, how is its output presented to the clinician, who keeps responsibility for the decision?
  4. What training do clinicians need to run a remote exam well, given that lack of training was among the barriers telehealth nonusers cited before the pandemic?

The signal to watch is the second device. Medaica's pitch depends on growing from one cleared exam into a set of connected tools, and the first third-party device or AI module that joins the stethoscope on its platform will show how fast that buildout is moving.

Featured companies

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

How Memorial Hermann measured $37,500 in AI scribe value per ER doctor

How Memorial Hermann measured $37,500 in AI scribe value per ER doctor

Memorial Hermann emergency physicians using Ambience Healthcare's AI documentation generated about $37,500 more in yearly productivity value than non-users. That figure is gross and comparative. It comes from billing data annualized over 160 shifts and excludes software costs, so buyers must build the cost side themselves.

  • 01Memorial Hermann's $37,500 per emergency physician is gross: the gap in work RVUs per clinical hour between AI documentation users and non-users, annualized over 160 ten-hour shifts, before any software or implementation cost.
  • 02Divided out, that gain comes to roughly $234 a shift or about $23 per clinical hour, a practical yardstick to hold against any all-in per-physician cost quote.
  • 03When a vendor puts fees at risk against outcomes, the comparison group, billing source and acuity adjustment become contract terms, because they decide what counts as a gain worth paying for.

Nov 21, 2026

Capsa's RoboPharma HV Wall is the first central fill system confirmed compatible with Parcel Health's paper vials

Capsa's RoboPharma HV Wall is the first central fill system confirmed compatible with Parcel Health's paper vials

Capsa Healthcare says its RoboPharma HV Wall is the first central fill automation system confirmed to fill Parcel Health’s Tully Tube, a paper prescription vial. The confirmation matters because central fill and mail order sites can only use containers their machines can handle—but this applies to the HV Wall specifically and is not a named production deployment. Buyers can see the vials at ASHP Midyear, Dec. 6–9.

  • 01A central fill site can't switch to a paper vial its automation can't handle. Confirmed machine compatibility is the gate, and the RoboPharma HV Wall is the first system through it for the Tully Tube.
  • 02The up to 71 percent plastic reduction per unit is a ceiling measured against a similar-size plastic vial, so operators modeling sustainability targets should ask for the comparison basis for their own vial sizes.

Nov 20, 2026

Luminopia's CEO says payer churn slows coverage and can require patching first

Luminopia's CEO says payer churn slows coverage and can require patching first

Luminopia co-founder and CEO Scott Xiao told HLTH's Partner Highlight series that short payer member tenure and a fragmented Medicaid leave pediatric amblyopia neglected. A 2025 JMCP payer roundtable recommended covering the FDA-authorized therapy but allowed step-edits, while PEDIG data show two-hour patching adds about 1.1 lines of acuity. Cleveland Clinic registry data report 1.8 lines of gain in severe cases.

  • 01A 2025 payer roundtable in the Journal of Managed Care & Specialty Pharmacy recommended plans cover Luminopia, yet said step-edits and letters of exception may still be required, with more than 9,000 prescriptions written since November 2022.
  • 02PEDIG's ATS05 trial put two hours of daily patching at 1.1 lines of gain over five weeks versus 0.5 lines for glasses alone, while a 2015 AAO review tied patching's poor compliance to social stigma.
  • 03S.1702, the Access to Prescription Digital Therapeutics Act of 2025, has sat in the Senate Finance Committee since May 8, 2025, leaving coverage negotiated plan by plan.

Nov 19, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512